Last update 01 Nov 2024

Alcon-Couvreur NV

Subsidiary Company|
1962|
Belgium

Overview

Tags

Eye Diseases
Nervous System Diseases
Cardiovascular Diseases
Small molecule drug
Single-chain FV antibody fragment

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases3
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug2
Single-chain FV antibody fragment1
Top 5 TargetCount
β1-adrenergic receptor(Beta-1 adrenergic receptor)1
VEGF-A(Vascular endothelial growth factor A)1

Related

5
Drugs associated with Alcon-Couvreur NV
Brolucizumab-dbll
Target
VEGF-A
Mechanism
VEGF-A inhibitors
Active Org.
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp. [+11]
Originator Org.
Novartis Pharma AG
Active Indication
Diabetic macular oedema [+7]
Inactive Indication
Macular Edema [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date07 Oct 2019
Brinzolamide/Brimonidine tartrate
Target
ADRA2 x CA2
Mechanism
ADRA2 agonists [+1]
Active Org.
Novartis Europharm Ltd. [+2]
Originator Org.
Novartis Pharma AG
Active Indication
Glaucoma [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date19 Apr 2013
Betaxolol Hydrochloride
Target
β1-adrenergic receptor
Mechanism
β1-adrenergic receptor antagonists
Active Org.
Alcon-Couvreur NV [+4]
Originator Org.
Novartis Pharma AG
Active Indication
Glaucoma [+5]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date30 Aug 1985
2
Clinical Trials associated with Alcon-Couvreur NV
CTR20150111 / CompletedPhase 3
布林佐胺10 mg/mL/溴莫尼定2 mg/mL混悬滴眼液与布林佐胺10 mg/mL混悬滴眼液 + 溴莫尼定2 mg/mL滴眼液对开角型青光眼/高眼压症疗效和安全性的比较
[Translation] Comparison of the efficacy and safety of brinzolamide 10 mg/mL/brimonidine 2 mg/mL suspension eye drops versus brinzolamide 10 mg/mL suspension eye drops + brimonidine 2 mg/mL eye drops for open-angle glaucoma/ocular hypertension
EUCTR2011-003816-21-BE / Not yet recruitingPhase 4
Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN® Solution without BAK, containing Polyquad® Preservative (0.004% travoprost) in Patients Previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution Monotherapy.
100 Clinical Results associated with Alcon-Couvreur NV
Login to view more data
0 Patents (Medical) associated with Alcon-Couvreur NV
Login to view more data
1
Literatures (Medical) associated with Alcon-Couvreur NV
Farmaceutisch Tijdschrift voor Belgie
A new β-blocker
100 Deals associated with Alcon-Couvreur NV
Login to view more data
100 Translational Medicine associated with Alcon-Couvreur NV
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
NDA/BLA
1
2
Approved
Other
2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free